Table 1.
Clinical characteristics of HCC patients by three cohorts
| CHCC-HBV cohort | TCGA cohort | ICGC cohort | |
|---|---|---|---|
| No. of patients | 159 | 365 | 231 |
| Age (median, range) | 54(20-81) | 61(16-90) | 69(31-89) |
| Gender (%) | |||
| Female | 31(19.5%) | 119(32.6%) | 61(26.4%) |
| Male | 128(80.5%) | 246(67.4%) | 170(72.6%) |
| AFP (ng/ml) | |||
| <200 | 89(56.0%) | NA | NA |
| >200 | 70(44.0%) | NA | NA |
| unknown | 0(0.0%) | NA | NA |
| Grade (%) | |||
| Grade 1 | NA | 55(15.1%) | NA |
| Grade 2 | NA | 175(47.9%) | NA |
| Grade 3 | NA | 118(32.3%) | NA |
| Grade 4 | NA | 12(3.3%) | NA |
| unknown | NA | 5(1.4%) | NA |
| Vascular Invasion | |||
| Yes | 122(76.7%) | NA | NA |
| No | 37(23.3%) | NA | NA |
| unknown | 0(0.0%) | NA | NA |
| TNM Stage (%) | |||
| I | 91(57.2%) | 170(46.6%) | 36(15.6%) |
| II | 14(8.8%) | 84(23.0%) | 105(45.5%) |
| III | 52(32.7%) | 83(22.7%) | 71(30.7%) |
| IV | 2(1.3%) | 4(1.1%) | 19(8.2%) |
| unknown | 0(0.0%) | 24(6.6%) | 0(0.0%) |
| Survival status | |||
| OS days (median) | 1020.9 | 556 | 780 |
| Censored (%) | 0(0.0%) | 126(34.5) | 42(18.2) |
TCGA, The Cancer Genome Atlas; ICGC, International Cancer Genome Consortium; AFP, Alpha Fetoprotein; TNM, Tumor Node Metastasis; NA, Not Applicable.